Larimar Therapeutics. Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from ...

Larimar Therapeutics LRMR is a clinical-stage company making medicines for rare diseases.The company has a Zacks Rank #1 (Strong Buy). Here we discuss some reasons why investing in LRMR stock now ...

We are maintaining a Hold rating on Larimar Therapeutics (NASDAQ:LRMR), with the caveat that we may begin accumulating shares if the stock continues to drop further.The company is developing ...

Larimar said that the dose-ascending study showed that daily subcutaneous injections of CTI-1601, at 50 mg and 100 mg doses, produced frataxin levels in peripheral tissues that were at the same ...

The larimar mine is rudimentary, covering an area of approximately 12 acres. Much of the muddy, sweaty work is done with pickaxes and shovels, though some portable power tools are used, too.

Larimar Therapeutics Inc has a consensus price target of $19.6 based on the ratings of 11 analysts. The high is $26 issued by Guggenheim on March 25, 2025.The low is $10 issued by Baird on March ...

JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp ...

Positive data from Larimar Therapeutics, Inc.'s phase 2 study on nomlabofusp for Friedreich's Ataxia suggests growth in the global market. Click for my LRMR update.